NOX-E36
Oncology (CCL2/MCP-1 target)
Pre-clinical/Phase 1Active
Key Facts
About TME Pharma
TME Pharma is a Berlin-based, publicly traded biotech advancing a novel approach to cancer treatment by targeting the tumor microenvironment. Its lead asset, NOX-A12, is a CXCL12-neutralizing Spiegelmer in Phase 2 development for glioblastoma, showing promising survival data in combination regimens. The company is pre-revenue, with a financial runway extending beyond 12 months as of early 2026, and faces the critical challenges of advancing late-stage trials and securing additional funding or partnerships.
View full company profile